Loading clinical trials...
Loading clinical trials...
A Multi-center, Prospective, Open-label, Randomized Study to Explore Efficacy and Safety of Baricitinib in Refractory Intestinal Behçet's Syndrome Patients
Conditions
Interventions
Baricitinib
Adalimumab
Locations
2
China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, China
Start Date
November 8, 2024
Primary Completion Date
June 30, 2027
Completion Date
June 30, 2028
Last Updated
February 27, 2025
Wenjie Zheng, M.D.
CONTACT
Lead Sponsor
Peking Union Medical College Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions